Mei-Fang Gong1,2,3, Rui-Ting Wen2,3,4, Ying Xu2,3,5, Jian-Chun Pan6, Ning Fei6, Yan-Meng Zhou7, Jiang-Ping Xu8, Jian-Hui Liang9, Han-Ting Zhang10,11,12. 1. Department of Neuropharmacology and Novel Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. 2. Department of Behavioral Medicine and Psychiatry, Blanchette Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, WV, 26506, USA. 3. Department of Physiology and Pharmacology, Blanchette Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, WV, 26506, USA. 4. Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China. 5. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, 14214, USA. 6. Brain Institute, School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. 7. Institute of Pharmacology, Taishan Medical University, Taian, Shandong, 271016, China. 8. Department of Neuropharmacology and Novel Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. jpx@smu.edu.cn. 9. Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, Beijing, 100191, China. liangjh@bjmu.edu.cn. 10. Department of Behavioral Medicine and Psychiatry, Blanchette Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, WV, 26506, USA. hzhang@hsc.wvu.edu. 11. Department of Physiology and Pharmacology, Blanchette Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, WV, 26506, USA. hzhang@hsc.wvu.edu. 12. Institute of Pharmacology, Taishan Medical University, Taian, Shandong, 271016, China. hzhang@hsc.wvu.edu.
Abstract
RATIONALE: Withdrawal symptoms stand as a core feature of alcohol dependence. Our previous results have shown that inhibition of phosphodiesterase-4 (PDE4) decreased ethanol seeking and drinking in alcohol-preferring rodents. However, little is known about whether PDE4 is involved in ethanol abstinence-related behavior. OBJECTIVE: The objective of this study was to characterize the role of PDE4 in the development of anxiety- and depressive-like behavior induced by abstinence from ethanol exposure in different animal models. METHODS: Using three rodent models of ethanol abstinence, we examined the effects of rolipram, a prototypical, selective PDE4 inhibitor, on (1) anxiety-like behavior induced by repeated ethanol abstinence in the elevated plus maze test in fawn-hooded (FH/Wjd) rats, (2) anxiety-like behavior in the open-field test and light-dark transition test following acute ethanol abstinence in C57BL/6J mice, and (3) anxiety- and depressive-like behavior induced by protracted ethanol abstinence in the elevated plus maze, forced-swim, and tail-suspension tests in C57BL/6J mice. RESULTS: Pretreatment with rolipram (0.1 or 0.2 mg/kg) significantly increased entries and time spent in the open arms of the elevated plus maze test in rats with repeated ethanol abstinence. Similarly, in mice with acute ethanol abstinence, administration of rolipram (0.25 or 0.5 mg/kg) dose-dependently increased the crossings in the central zone of the open-field test and duration and transitions on the light side of the light-dark transition test, suggesting anxiolytic-like effects of rolipram. Consistent with these, chronic treatment with rolipram (0.1, 0.3, or 1.0 mg/kg) increased entries in the open arms of the elevated plus maze test; it also reduced the increased duration of immobility in both the forced-swim and tail-suspension tests in mice after protracted ethanol abstinence, suggesting antidepressant-like effects of rolipram. CONCLUSIONS: These results provide the first demonstration for that PDE4 plays a role in modulating the development of negative emotional reactions associated with ethanol abstinence, including anxiety and depression. PDE4 inhibitors may be a novel class of drugs for treatment of alcoholism.
RATIONALE: Withdrawal symptoms stand as a core feature of alcohol dependence. Our previous results have shown that inhibition of phosphodiesterase-4 (PDE4) decreased ethanol seeking and drinking in alcohol-preferring rodents. However, little is known about whether PDE4 is involved in ethanol abstinence-related behavior. OBJECTIVE: The objective of this study was to characterize the role of PDE4 in the development of anxiety- and depressive-like behavior induced by abstinence from ethanol exposure in different animal models. METHODS: Using three rodent models of ethanol abstinence, we examined the effects of rolipram, a prototypical, selective PDE4 inhibitor, on (1) anxiety-like behavior induced by repeated ethanol abstinence in the elevated plus maze test in fawn-hooded (FH/Wjd) rats, (2) anxiety-like behavior in the open-field test and light-dark transition test following acute ethanol abstinence in C57BL/6J mice, and (3) anxiety- and depressive-like behavior induced by protracted ethanol abstinence in the elevated plus maze, forced-swim, and tail-suspension tests in C57BL/6J mice. RESULTS: Pretreatment with rolipram (0.1 or 0.2 mg/kg) significantly increased entries and time spent in the open arms of the elevated plus maze test in rats with repeated ethanol abstinence. Similarly, in mice with acute ethanol abstinence, administration of rolipram (0.25 or 0.5 mg/kg) dose-dependently increased the crossings in the central zone of the open-field test and duration and transitions on the light side of the light-dark transition test, suggesting anxiolytic-like effects of rolipram. Consistent with these, chronic treatment with rolipram (0.1, 0.3, or 1.0 mg/kg) increased entries in the open arms of the elevated plus maze test; it also reduced the increased duration of immobility in both the forced-swim and tail-suspension tests in mice after protracted ethanol abstinence, suggesting antidepressant-like effects of rolipram. CONCLUSIONS: These results provide the first demonstration for that PDE4 plays a role in modulating the development of negative emotional reactions associated with ethanol abstinence, including anxiety and depression. PDE4 inhibitors may be a novel class of drugs for treatment of alcoholism.
Entities:
Keywords:
Anxiety; Behavior; Depression; Ethanol abstinence; Mei-Fang Gong, Rui-Ting Wen, and Ying Xu contributed equally to this work.; Phosphodiesterase-4 (PDE4); Rodents; Rolipram
Authors: David H Overstreet; Amir H Rezvani; Elvan Djouma; Abbas Parsian; Andrew J Lawrence Journal: Neurosci Biobehav Rev Date: 2006-09-18 Impact factor: 8.989
Authors: Richard L Bell; Marcelo F Lopez; Changhai Cui; Mark Egli; Kirk W Johnson; Kelle M Franklin; Howard C Becker Journal: Addict Biol Date: 2013-11-11 Impact factor: 4.280
Authors: Ana González-Cuello; Lorenzo Sánchez; Jesús Hernández; M Teresa Castells; M Victoria Milanés; M Luisa Laorden Journal: Eur J Pharmacol Date: 2007-06-09 Impact factor: 4.432
Authors: Yuri A Blednov; Adriana J Da Costa; Tamara Tarbox; Olga Ponomareva; Robert O Messing; R Adron Harris Journal: Alcohol Clin Exp Res Date: 2018-03-24 Impact factor: 3.455
Authors: Amanda J Roberts; Sophia Khom; Michal Bajo; Roman Vlkolinsky; Ilham Polis; Chelsea Cates-Gatto; Marisa Roberto; Donna L Gruol Journal: Brain Behav Immun Date: 2019-08-19 Impact factor: 7.217
Authors: Solal Bloch; Katherine M Holleran; Thomas L Kash; Elena M Vazey; Jennifer A Rinker; Christina L Lebonville; Krysten O'Hara; Marcelo F Lopez; Sara R Jones; Kathleen A Grant; Howard C Becker; Patrick J Mulholland Journal: Alcohol Date: 2022-02-15 Impact factor: 2.405
Authors: Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray Journal: Brain Behav Immun Date: 2021-07-31 Impact factor: 19.227